Here, we will revisit the excitotoxic hypothesis in HD through the phosphatase point of view, and we will also pay attention to the importance of phosphorylation in reducing the toxicity of mhtt. We will discuss the results obtained in both exon-1 and full-length HD models, and we will integrate the potential contribution of an imbalance between the activity of phosphatases and kinases to HD pathophysiology.
Introduction
The molecular bases that account for the preferential neurodegeneration of striatal mediumsized spiny neurons (MSNs) in Huntington's Disease (HD) are still unknown, and different mechanisms have been proposed to contribute to the neurodegenerative process. These include mitochondrial dysfunction and metabolic impairment, transcriptional dysregulation, altered expression of trophic factors, dopamine toxicity, oxidative stress, and changes in autophagy, and huntingtin (htt) phosphorylation. In addition, excitotoxicity through the overactivation of N-methyl-D-aspartate (NMDA) receptors (NMDARs) has also been proposed to contribute to the preferential loss of these neurons (for review see Ehrnhoefer et al., 2011; Jin & Johnson, 2010; Perez-Navarro et al., 2006; Renna et al., 2010; Rosenstock et al., 2010; Weir et al., 2011) .
Some of these mechanisms are controlled by the attachment/removal of phosphate groups through the action of protein kinases and protein phosphatases, respectively. Therefore, alterations in their levels/activity in the presence of mutant htt (mhtt) can impact on cell survival.
Htt is expressed in almost all tissues, has a widespread distribution in the brain, its expression levels are similar in control individuals and in HD patients, with no evidence of increased htt expression in the brain regions most affected in HD (reviewed by Han et al., 2010) . These evidences indicate that differences in mhtt expression do not contribute to the increased vulnerability of MSNs in HD. Conversely, several cell-type specific features including morphological, biochemical, and functional characteristics might play a role in rendering MSNs more vulnerable to the toxic effects of mhtt (Han et al., 2010) . In this line, it is relevant in context of the present review to mention that the phosphatases calcineurin (also known as protein phosphatase 2B -PP2B) (Goto et al., 1987) and striatal-enriched protein tyrosine phosphatase (STEP) (Lombroso et al., 1991) are enriched in MSNs, suggesting that variations in their expression levels/activity can impact seriously in the function and viability of these neurons.
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2007; Luo et al., 2005) , ERK1 (Schilling et al., 2006) , and CK2 (Atwal et al., 2011) . In contrast, the phosphatases acting on these residues are still unknown (reviewed by Ernhoefer et al., 2011) . Fig. 1 . Regulation of phosphatases in striatal neurons by NMDAR and dopamine D1 receptor (DR1) stimulation. Stimulation of NMDARs activates PP2A and calcineurin, which in turn will activate STEP and PP1. DR1 stimulation activates PP2A, and indirectly blocks PP1 activity. Several pathways and targets have been omitted for simplification. PDEs: Phosphodiesterases; AC: Adenylyl cyclase; PKA: cAMP-dependent protein kinase; CaM: calmodulin; DARPP-32: dopamine-and cAMP-regulated phosphoprotein of 32 kDa
Ser/Thr phosphatases
Ser/Thr phosphatases catalyze dephosphorylation reactions on phospho-Ser and phosphoThr residues. They are classified into three families: protein phosphatase Mg 2+ -activated (PPM), phosphoprotein phosphatases (PPPs) and the aspartate-based phosphatases represented by FCP/SCP (TFIIF-associating component of RNA polymerase II CTD phosphatase/small CTD phosphatase). The PPM family includes PP2C, pyruvate dehydrogenase phosphatase, and PP2C-"like" phosphatases, and the major phosphatases in the PPP family are PP1, PP2A and calcineurin (reviewed by McConnell & Wadzinski, 2009 ). PP1, PP2A and calcineurin are composed of catalytic and regulatory subunits, whereas PP2C exists as a monomer devoid of regulatory subunits. In the brain, the activity of these phosphatases is regulated by the regulatory subunit, interacting partners, scaffolding proteins and/or specific endogenous activators/inhibitors (reviewed by Gee & Mansuy, 2005) . These phosphatases are implicated in the regulation of excitotoxicity, synaptic plasticity and cell survival, and are altered in neurodegenerative disorders such as Alzheimer's Disease (Ducruet et al., 2005; Iqbal & Grundke-Iqbal, 2007; F. Liu et al., 2006; Tian & Wang, 2002 ), Parkinson's Disease (Lou et al., 2010; Wera & Neyts, 1994) and HD (Metzler et al., 2010; Pineda et al., 2009; Saavedra et al., 2010; Xifro et al., 2008; 2009 Wu et al., 2002 Fan et al., 2008 Calcineurin (Xifro et al., 2009 ) and PHLPP1 (Saavedra et al., 2010) protein levels, and STEP mRNA levels (Hodges et al., 2006) are also decreased in the caudate/putamen of HD patients. HEK: human embryonic kidney; Q: glutamine; Tet/HD94: conditional mouse model of HD 
Calcineurin
Calcineurin is a Ser/Thr phosphatase activated by calcium/calmodulin, highly expressed in the brain, and abundant in the cytosol, and in pre-synaptic and post-synaptic terminals (Mansuy, 2003; Shibasaki et al., 2002) . It is a heterodimer composed by a calmodulin-binding catalytic subunit, calcineurin A, and an intrinsic calcium-binding regulatory subunit, calcineurin B. The dependence on calcium distinguishes calcineurin from spontaneously active PP2A and from Mg 2+ -dependent PP2C. The binding of the calcium/calmodulin complex to calcineurin A with high affinity leads to the release of the auto-inhibitory domain from the active site and calcineurin activation. In addition to activation by calcium, calcineurin can also be activated by caspase-or calpain-mediated proteolysis, which originate a constitutively active form, insensitive to calcium/calmodulin (reviewed by A. Mukherjee & Soto, 2011) .
Calcineurin is the only calcium-dependent phosphatase present in neurons, which confers it an important role in the maintenance of cellular homeostasis, and in neuronal activity (Mansuy, 2003; Shibasaki et al., 2002) . Calcineurin also modulates gene expression by the regulation of transcription factors such as the cAMP responsive element binding protein (CREB) and the nuclear factor of activated T-cell (NFAT) (reviewed by A. Mukherjee & Soto, 2011) .
Calcineurin is highly expressed in the striatum, and in particular in MSNs (Goto et al., 1987) . The participation of calcineurin in neuronal death induced by insults that elevate intracellular calcium levels (Ankarcrona et al., 1996; Butcher et al., 1997; Dawson et al., 1993; Shamloo et al., 2005; Shibasaki & McKeon 1995; Wood & Bristow 1998; H. Y. Wu et al., 2004) suggests that this phosphatase might be a good candidate to participate in the excitotoxic events associated with HD.
The pro-apoptotic function of calcineurin has been linked to the dephosphorylation of selected substrates related to apoptosis, such as Bad (a pro-apoptotic Bcl-2 family member) (Springer et al., 2000; H. G. Wang et al., 1999) , death-associated protein kinase (Shamloo et al., 2005; Xifro et al., 2008) , cdk5 (Nishi et al., 2002) or transcription factors, such as NFAT (Beals et al., 1997) . Importantly, calcineurin also dephosphorylates mhtt at Ser421 (Pardo et al., 2006) . Consistent with the neuroprotective role of htt phosphorylation at Ser421 (Humbert et al., 2002; Rangone et al., 2004; Warby et al., 2005) , inhibition of calcineurin activity in HD neuronal cells restores htt phosphorylation levels at Ser421, and prevents polyglutamine (polyQ)-mediated cell death of striatal neurons (Pardo et al., 2006) . Moreover, inhibition of calcineurin by FK506 leads to sustained phosphorylation of mhtt at Ser421 and reestablishes BDNF transport in rat primary neuronal cultures expressing mhtt, and in mouse cortical neurons from Hdh Q111/Q111 mice (Pineda et al., 2009) . Recently, calcineurin has been shown to dephosphorylate the pro-fission dynamin related protein 1 (Cereghetti et al., 2008) , which increases its mitochondrial translocation and activation, leading to mitochondrial fragmentation and contributing to the hypersensitivity of HD mitochondria to apoptosis (Costa et al., 2010) . In fact, mitochondrial fragmentation can be prevented by genetic or pharmacological inhibition of calcineurin (Costa et al., 2010) .
Studies using primary striatal cultures from YAC transgenic mice show that NMDAR stimulation produces a polyQ length-dependent increase in cell death (Shehadeh et al., 2006; Zeron et al., 2002) . These observations were extended by our studies showing that STHdh Q111/Q111 cells are more susceptible to NMDA-mediated cell death than STHdh Q7/Q7 cells, a phenomenon related to higher calcineurin A protein levels and calcineurin activity in mhtt knock-in striatal cells than in wild-type cells (Xifro et al., 2008) . Interestingly, although calcineurin protein levels are similar in mouse brains containing wild-type and mhtt, Hdh Q111/Q111 and Hdh Q111/Q7 mice have significantly higher levels of calcineurin activity in the cortex than Hdh Q7/Q7 mice (Pineda et al., 2009) . In agreement with these reports showing increased calcineurin activity, the levels of the negative regulator of calcineurin RCAN1-1L are significantly down-regulated in HD brain samples (Ermak et al., 2009 ). Additionally, a dysregulation in the levels of cytosolic calcium, the calcineurin activator, was also reported in primary cultures from YAC128 mice (Tang et al., 2005) . Calcineurin can play a toxic role in striatal cells expressing full-length mhtt at two different levels. High levels of calcineurin increase the susceptibility to excitotoxicity (Xifro et al., 2008) and, on the other hand, calcineurin can increase mhtt toxicity directly by dephosphorylation of its Ser421 (Ermak et al., 2009; Pardo et al., 2006; Pineda et al., 2009) , or indirectly by regulating proteins that modulate mhtt toxicity, such as cdk5 (Luo et al., 2005) or calpain (Gafni et al., 2004) .
Conversely, calcineurin A mRNA levels are decreased in human HD samples (Hodges et al., 2006) . Similarly, in the striatum of R6 mouse models of HD, which express the exon-1 mhtt fragment, calcineurin levels are lower than in the wild-type mice striatum (HernandezEspinosa & Morton, 2006; Lievens et al., 2002; Luthi-Carter et al., 2000; Xifro et al., 2009 ). Interestingly, these mice are resistant to excitotoxicity (Hansson et al., 1999 (Hansson et al., , 2001 TorresPeraza et al., 2008) . These findings suggest a dual regulation of calcineurin A expression during the progression of the disease, with high levels at early stages resulting in high susceptibility to excitotoxicity (Xifro et al., 2008) , and low levels at end stages participating in the resistance to excitotoxic-induced cell death (Xifro et al., 2009) (Figure 2 ). Thus, it would be relevant to study whether this dual calcineurin regulation also occurs in fulllength mouse models of HD as YAC128 mice, which were reported to be more sensitive to excitotoxicity than controls at presymptomatic stages, but resistant to intrastriatal quinolinic acid (an NMDAR agonist) injection when signs of HD are obvious . Consistent with resistance to excitotoxicity , reduced calcineurin activity has been shown in the striatum of YAC128 mice at 12 months of age (Metzler et al., 2010) .
Studies performed in in vivo models of HD confirm the important role played by calcineurin in the excitotoxic-mediated cell death of striatal neurons. Calcineurin inhibition in wild-type mice drastically reduces quinolinic acid-induced striatal cell death (Xifro et al., 2009 ). Moreover, calcineurin activation induced by intrastriatal quinolinic acid injection in R6/1 mice is lower than in wild-type mice (Xifro et al., 2009) , which is consistent with R6/1 animals being resistant to excitotoxicity (Hansson et al., 1999 (Hansson et al., , 2001 ).
However, the role of calcineurin in HD remains controversial as calcineurin inhibition has been reported to have protective (Costa et al., 2010; Ermak et al., 2009; Pardo et al., 2006; Pineda et al., 2009; Xifro et al., 2008) or worsening (Hernandez-Espinosa & Morton, 2006) effects in HD models. The participation of reduced calcineurin activity caused by alteration of calcineurin A expression in the pathophysiology of HD, and in the excitotoxic resistance observed in exon-1 mouse models (Xifro et al., 2009) , together with the finding that treatment with calcineurin inhibitors accelerates the progression of the disease in R6/2 mice (Hernandez-Espinosa & Morton, 2006) suggest that decreased levels of calcineurin could result in striatal neuronal dysfunction affecting the onset of motor alterations. However, since both FK506 and cyclosporine A, that does not cross the blood-brain barrier, have the same negative effect (Hernandez-Espinosa & Morton, 2006 ) the harmful effect of calcineurin inhibition reported in this study might be unrelated to the effect of these inhibitors in the CNS.
Taken together, these findings suggest calcineurin as an important therapeutic target for HD, by its participation in excitotoxic events, as well as by its action on phosphorylated mhtt (Ser421) to increase toxicity. Fig. 2 . Changes in striatal calcineurin levels during HD progression, and involvement in excitotoxicity. Results from Xifro et al. (2008) suggest that at early stages of HD calcineurin levels are increased and striatal neurons are more susceptible to NMDA-induced excitotoxicity. In contrast, at late stages, calcineurin levels are decreased and participate in the resistance of striatal neurons to NMDA-induced excitotoxicity (Xifro et al., 2009) . CaM: calmodulin.
Pleckstrin homology (PH) domain leucine-rich repeat protein phosphatase (PHLPP)
PHLPPs constitute a subfamily within the PP2C phosphatase family. PHLPPs require Mg 2+ and Mn 2+ for their catalytic activity, and are not inhibited by traditional phosphatase inhibitors such as okadaic acid (Brognard et al., 2007; Gao et al., 2005) . This family comprises three members: PHLPP1 PHLPP1and PHLPP2. PHLPP1 and PHLPP1 are splice variants from the same gene but have different sizes, whereas PHLPP2 is a different gene product and has the same domain composition of PHLPP1 (Brognard et al., 2007) . PHLPP1
and PHLPP2 have an identical domain structure with a PH domain (sharing 63% amino identity) followed by a region of leucine-rich repeats, a PP2C phosphatase domain (sharing 58% amino identity) and a C terminal PDZ ligand. In addition, PHLPP1and PHLPP2 contain a Ras-association domain preceding the PH domain .
PHLPPs are expressed in the majority of human tissues and are localized in different cellular compartments such as cytosol, nucleus and membrane (Brognard et al., 2007; . In the CNS, PHLPP1 was the first identified as an mRNA that oscillated in a circadian rhythm-dependent manner in the suprachiasmatic nucleus (SCN) and was named SCOP (SCN circadian oscillatory protein) (Shimizu et al., 1999) . PHLPP1 /SCOP is expressed in various brain regions with a relative enrichment in hippocampus and cerebellum (Shimizu et al., 1999) . Its expression is highly concentrated in neurons, and is present in nuclear, mitochondrial and cytosolic fractions (Shimizu et al., 1999) , as well as in membrane rafts (Shimizu et al., 2003) . Recently, PHLPP1 and PHLPP2 have been shown to be also expressed in hippocampal neurons (Jackson et al., 2009; with PHLPP1 as the most abundantly expressed in the adult (Jackson et al., 2010) . Although PHLPP1 and 2 can be found in the cytosolic fraction, only PHLPP1 can be localized in the nucleus of hippocampal neurons (Jackson et al., 2010) . In addition, we have detected PHLPP1 in the cortex and striatum of adult mice (Saavedra et al., 2010) .
So far, the known substrates for PHLPPs are the kinases Akt (also known as protein kinase B), and protein kinase C (PKC). Akt, the first identified substrate of PHLPP (Gao et al., 2005) , is a key regulator of a wide range of cellular processes including growth, proliferation, metabolism, cell cycle progression, and survival. Thus, altered Akt activity has been associated with cancer and other disease conditions such as diabetes and neurodegenerative diseases (Liao & Hung, 2010) . For its full catalytic activity, Akt requires phosphorylation at Thr308 in the activation loop and at Ser473 in the hydrophobic motif (Brazil & Hemmings, 2001) . Its activation depends on the PI3-kinase, which produces the lipid second messenger PtdIns-3, 4, 5-P3 (PIP3) that interacts with the PH domain of Akt and recruits the kinase to the plasma membrane (Sancak et al., 2008) . Subsequently, the Thr308 residue is phosphorylated by membrane-localized 3-phosphoinositide-dependent protein kinase 1 (PDK1) (Alessi et al., 1997; Calleja et al., 2007) and the Ser473 residue is phosphorylated by mTORC2 (Sarbassov et al., 2005) (Figure 3 ). PHLPPs specifically dephosphorylate the hydrophobic motif of Akt, resulting in a decrease of its activity (Gao et al., 2005) , whereas the Thr308 site is dephosphorylated by PP2A (Bayascas & Alessi, 2005) . PKC, the other PHLPPs substrate, consists in a Ser/Thr family of phosphorylating enzymes ubiquitously expressed and implicated in multiple cellular functions. There are 12 isoforms of PKC termed (1) calcium-dependent or classical PKCs, cPKCs (2) calcium-independent or novel PKCs, nPKCs, and (3) atypical PKCs, aPKCs (Amadio et al., 2006; Pearce et al., 2010) . PKC isoforms, like Akt, are also activated by the phosphorylation of the activation segment and hydrophobic motif (Newton, 2003) . PDK1 phosphorylates the activation segment (Dutil et al., 1998; Le Good et al., 1998) , and there is increasing evidence that mTORC2 phosphorylates the hydrophobic motif of at least some isoforms (Sarbassov et al., 2004; Guertin et al., 2006) . The phosphorylation of the hydrophobic motif regulates the amplitude of PKC signaling by controlling the stability of the kinase. Both PHLPP1 and PHLPP2 dephosphorylate the hydrophobic motif of conventional and novel PKC isoforms, but not atypical PKC isoforms (Gao et al., 2008) . This dephosphorylation induces the degradation of PKC. Thus, depletion of PHLPP1 or PHLPP2 leads to a robust increase in PKC levels (Gao et al., 2008) .
Members of the AGC kinase family like p70S6K, SGK or p90RSK, which have hydrophobic phosphorylation motifs, are other potential substrates of PHLPPs . In addition to the dephosphorylation of Akt and PKC, PHLPP1/SCOP negatively regulates the Ras-Raf-MEK-ERK pathway by interacting directly with Ras (Shimizu et al., 2003) .
In the CNS, PHLPPs participate in the regulation of the circadian clock (Shimizu et al., 1999) , learning and memory (Shimizu et al., 2007) , and survival (Jackson et al., 2009; Saavedra et al., 2010) . In HD, we have shown that PHLPP1 is reduced in cellular as well as in HD mouse models, and in the putamen of HD patients (Saavedra et al., 2010) . STHdh Q111/Q111 cells display decreased levels of PHLPP1 compared with STHdh Q7/Q7 cells. Similarly, we detected reduced levels of PHLPP1 in the striatum of Hdh Q111/Q111 mice (at 5 months of age), and also in the striatum of the exon-1 mouse models R6/1 (from 12 to 30 weeks of age), R6/1:BDNF +/-(from 12 to 30 weeks of age), R6/2 (at 12 weeks of age) and Tet/HD94 (at 22 months of age). In addition, PHLPP1 levels are also decreased in the cortex and hippocampus of R6/1 mice at 12 and 30 weeks of age. PHLPP1 expression was regulated by mhtt at the transcriptional level since we also detected decreased PHLPP1 mRNA levels in the striatum of R6/1 mice (Saavedra et al., 2010) . We speculated that the down-regulation of PHLPP1 mRNA levels could be related with decreased activity of the transcription factor NF-Y, since this transcription factor is sequestered in mhtt aggregates (Yamanaka et al., 2008) . It has recently been shown that the expression of PHLPP is controlled by mammalian target of rapamycin (mTOR)-dependent protein translation in colon and breast cancer cells (J. Liu et al., 2011) . Interestingly, mTOR activity is reduced in HD (Ravikumar et al., 2004) . Thus, it is tempting to speculate that this mechanism could also be involved in the down-regulation of PHLPP1 levels. In good correlation with decreased levels of PHLPP1 in the striatum, we observed increased phosphorylation levels of Akt (Ser473) and of its targets GSK3 (Ser9) and FoxO (Ser256). Although PHLPP1 levels were down-regulated in the cortex and hippocampus of R6/1 mice we did not observe changes in pAkt (Ser473) levels indicating that a reduction of PHLPP1 levels may not be enough to increase pAkt (Ser473) levels in vivo (Saavedra et al., 2010) . In addition, in the striatum of Tet/HD94 mice, we observed that after shutting-down the expression of mhtt, PHLPP1 protein levels returned to wild-type levels but pAkt (Ser473) up-regulation was only partially reduced (Saavedra et al., 2010) . Taken together, these results suggest that increased levels of pAkt is a specific mechanism taking place in striatal neurons expressing mhtt, which could be the sum of increased activation of kinases that phosphorylate Akt and decreased levels of PHLPP1 . Since Akt activation is one of the main mechanisms to prevent neuronal death during injury (Chong et al., 2005) , and many transgenic HD mouse models show little, if any, striatal cell death (Canals et al., 2004; Diaz-Hernandez et al., 2005; GarciaMartinez et al., 2007; Mangiarini et al., 1996; Martin-Aparicio et al., 2001 ), our results suggest that increased Akt activation could counteract mhtt toxicity.
In addition, we showed that decreased levels of PHLPP1 could help to maintain high levels of pAkt (Ser473) in R6/1 striatum after excitotoxicity, contributing to prevent cell death induced by NMDARs overstimulation (Saavedra et al., 2010) .
Conversely, we found unchanged levels of PHLPP2 in the striatum in R6/1 mice at different stages of the disease (8, 12, 20 and 30 weeks of age), while cortical levels are decreased at 12 and 30 weeks of age. Akt is phosphorylated at Thr308 (T308) by PDK1 and dephosphorylated by PP2A, whereas the Ser473 residue (S473) is phosphorylated by mTORC2 and dephosphorylated by PHLPP. Once activated, Akt prevents apoptosis through the phosphorylation of several targets such as GSK3 and FoxO1. (B) Control of Akt phosphorylation in striatal cells expressing mhtt. In the presence of mhtt PHLPP1 levels are decreased and contribute to maintain high levels of Akt phosphorylated at S473 that through increased levels of phosphorylated GSK3 and FoxO1 may delay striatal cell death. Results obtained by analyzing different brain regions suggest that mhtt could also affect the activation of kinases that phosphorylate Akt in the striatum, but not in other brain regions (Saavedra et al., 2010) .
PP1 and PP2A
PP1 and PP2A account for the majority of Ser/Thr phosphatase activity in mammalian cells, and are involved in diverse cellular processes such as cell growth and proliferation, development, DNA replication and repair, metabolism, neural signaling, and apoptosis. The activity of these two phosphatases can be blocked by okadaic acid and caliculin at different IC50 values (Sheppeck et al., 1997) . The specific oligomeric composition of PP1 and PP2A holoenzyme is important to control their phosphatase activity. Functional PP1 enzyme consists of a catalytic subunit (PP1c) and a regulatory subunit (R subunit). The PP1c associates with more than 50 proteins that regulate substrate specificity and subcellular localization (Ceulemans & Bollen, 2004; P.T. Cohen, 2002) . The interaction of PP1c with its regulatory subunit can also influence substrate specificity. In addition, its activity is regulated by endogenous inhibitory proteins like inhibitor-1 (P. Cohen & Nimmo, 1978) , inhibitor-2 (Foulkes & P. Cohen, 1980) , CPI-17 (Eto et al., 1997) , and DARPP-32 (Walaas & Greengard, 1991) , which is highly expressed in MSNs. PP2A exists in two forms: a core dimer and a heterotrimeric holoenzyme. The PP2A core dimer is composed by the scaffolding A subunit and the catalytic C subunit and associates with a regulatory B subunit to generate the heterotrimeric holoenzyme, which is the predominant form of PP2A in the cell. PP2A regulatory B subunits are divided into four different families and play a crucial role in the subcellular localization of PP2A. They can also alter the overall shape of the catalytic subunit as well as enzyme kinetics (reviewed by McConnell & Wadzinski, 2009; Shi, 2009 ).
In the CNS, PP1 and PP2A dephosphorylate neurotransmitter receptors and proteins localized at the post-synaptic site, thus participating in the regulation of excitatory and inhibitory transmission. PP1 dephosphorylates CaMKII when bound to post-synaptic density, whereas soluble or synaptosomal CaMKII is deposphorylated by PP2A (Shields et al., 1985; Strack et al., 1997) . In addition, both phosphatases regulate NMDARs-mediated synaptic currents in an activity-dependent manner (L. Y. Wang et al., 1994; Westphal et al., 1999) . PP1 dephosphorylates GABA receptor subunits (X. Wang et al., 2002) and downregulates AMPA receptor activity and trafficking by dephosphorylation of the GluR1 subunit (reviewed by Mansuy & Shenolikar, 2006) . In addition, PP1 and PP2A activity can promote apoptosis (reviewed by Garcia et al., 2003; Klumpp & Krieglstein, 2002) . PP1 dephosphorylates the pro-apoptotic protein Bad with its consequent activation, and PP2A dephosphorylates the anti-apoptotic proteins Akt and Bcl-2 inactivating them. PP2A can also regulate the activity of a large number of kinases, such as ERK, PKA and p38 (reviewed by Millward et al., 1999) , all of them important to neuronal survival and function.
Recently, the number of targets of PP1 and PP2A has been extended since both proteins dephosphorylate htt in situ and after excitotoxic stimulation of NMDARs (Metzler et al., 2010 ; see Figure 1 ). Metzler and colleagues (2010) showed that NMDARs overstimulation induces a decrease of phtt (Ser421) in primary neurons from wild-type and YAC128 transgenic mice. In addition, dephosphorylation of htt (Ser421) was also observed in YAC128 transgenic mice after quinolinic acid injection in the striatum. Dephosphorylation of htt after excitotoxicity seems to participate in the induction of cell death since blockade of PP1 and PP2A activity protects YAC128 striatal neurons from NMDA-induced cell death in vitro. Moreover, they showed that dopamine modulates htt phosphorylation in the striatum through the regulation of the PP1 inhibitor DARPP-32. These authors also observed a decrease in the PP1 substrate pCREB, which together with decreased levels of DARPP-32 in YAC128 striatum suggested an altered regulation of phosphatase activity in HD. However, they could not detect changes in the activity of PP1 and PP2A in YAC128 mice striatum. Although these results point to a role of htt dephosphorylation in excitotoxic-induced cell death in the striatum, it remains to be shown whether inhibition of PP1 and PP2A is also neuroprotective in vivo. In addition, it would be interesting to investigate whether dephosphorylation of mhtt takes place in the striatum of YAC128 mice when they are resistant to excitotoxicity. PP2A protein levels have also been analyzed in the striatum of R6/1 mice. Similarly to that observed in YAC128 mice striatum (Metzler et al., 2010) , no changes in PP2A protein levels have been detected in R6/1 mouse striatum at 4, 8, 12, 16 and 30 weeks of age compared with their littermate controls (Saavedra et al., 2010) .
Tyrosine phosphatases
Tyrosine (Tyr) phosphatases, encoded by about 107 genes in the human genome (Alonso et al., 2004; Andersen et al., 2004) , have the ability to hydrolyze p-nitrophenyl phosphate, are inhibited by vanadate and are insensitive to okadaic acid. They are classified into three groups: (1) Cytoplasmic, (2) Receptor-like, and (3) Dual specificity phosphatases, which dephosphorylate Ser, Thr and Tyr residues that are in close proximity. The specificity of Tyr phosphatases is regulated by several molecular strategies such as preferential recognition of phosphopeptides, cell-type and organelle-specific expression, and assembly with other proteins (for review see S. Z. Y. Zhang, 2002) . These phosphatases play important roles in the development and function of the CNS (Ensslen-Craig & Brady-Kalnay, 2004; S. , and have been suggested to function as neuroprotectants. STEP, the SH2-containing Tyr phosphatases SHP1 and SHP2, and protein Tyr phosphatase alpha are among the protective candidates. However, protein Tyr phosphatase alpha and phosphatase and tensin homolog deleted from chromosome 10 (PTEN) may also induce neurotoxicity (Gee & Mansuy, 2005) . Increased Tyr phosphorylation has been suggested to induce neuronal cell death in cerebral ischemia (Ohtsuki et al., 1996; R. Paul et al., 2001 ) and after epileptiform activity (Chun et al., 2004; Sanna et al., 2000) . In addition, alterations in protein Tyr phosphatases are considered to be involved in the etiology of neural disorders such as Alzheimer's Disease (Kerr et al., 2006; Lee et al., 2004 ), Parkinson's Disease (Herradon & Ezquerra, 2009 ) and HD (Saavedra et al., 2011; Z. L. Wu et al., 2002) .
STEP
STEP, encoded by the Ptpn5 gene, is a brain-specific Tyr phosphatase involved in neuronal signal transduction. STEP plays an important role in synaptic plasticity through the opposition to synaptic strengthening (Braithwaite et al., 2006a) . Additionally, STEP has been implicated in susceptibility to cell death through the modulation of ERK1/2 signaling (Choi et al., 2007; Saavedra et al., 2011) , while other studies suggest that STEP can play a role in neuroprotection through the regulation of the p38 pathway (Poddar et al., 2010; Xu et al., 2009) . The mechanism underlying the ability of STEP to regulate both pro-survival and procell death pathways has been recently elucidated (Xu et al., 2009 ; see details below). (Lombroso et al., 1991) , and expressed at lower levels in the cortex, hippocampus and amygdala (Boulanger et al., 1995) . STEP mRNA is alternatively spliced into several STEP isoforms (Bult et al., 1997; Sharma et al., 1995) that are differentially targeted to the post-synaptic density (Oyama et al., 1995) , extra-synaptic and cytosolic compartments Xu et al., 2009 ). The major isoforms are STEP 46 , the cytosolic isoform, and STEP 61 , which is membrane-associated through the additional 172 amino acids in the N-terminus (Bult et al., 1997) . Both isoforms are expressed in the striatum, whereas other brain regions only express STEP 61 (Boulanger et al., 1995) . STEP activity is regulated through phosphorylation/dephosphorylation of a Ser residue within its kinase interacting motif (KIM) domain. Stimulation of D1Rs activates PKA (Stoof & Kebabian, 1981) , which phosphorylates STEP thereby inactivating it (S. Paul et al., 2000) ( Figure 1 ). In contrast, stimulation of NMDARs results in the dephosphorylation and activation of STEP through a calcineurin/PP1 pathway (S. Valjent et al., 2005) (Figure 1 ). Additionally, STEP activity is also regulated by proteolytic cleavage (Xu et al., 2009 ), ubiquitin-proteasome degradation S. Mukherjee et al., 2011; Xu et al., 2009) , local translation (Y. Zhang et al., 2008) , and oligomerization .
STEP is enriched in MSNs
Once activated, STEP dephosphorylates the glutamate receptor subunits NR2B (Braithwaite et al., 2006b; Pelkey et al., 2002; Snyder et al., 2005) and GluR2 (Y. Zhang et al., 2008) , leading to their endocytosis, and the kinases ERK1/2, p38 and Fyn, thereby controlling the duration of their signal (Munoz et al., 2003; Nguyen et al., 2002; Pulido et al., 1998) (Figure 1 ).
The enrichment of STEP in MSNs, its role in the regulation of key substrates implicated in neuronal function, together with the fact that both dopaminergic and glutamatergic systems regulate STEP activity and are affected in HD patients and mouse models (Andre et al., 2010; Fan & Raymond, 2007; Jakel & Maragos, 2000) prompted us to study the possible role of STEP in the pathophysiology of HD (Saavedra et al., 2011) . In fact, previous studies showed decreased mRNA levels of STEP in the caudate nucleus and cortex of HD patients (Hodges et al., 2006) , in the striatum of R6 mice (Desplats et al., 2006; Luthi-Carter et al., 2000) , and in primary striatal neurons overexpressing htt171-82Q (Runne et al., 2008) . Our results show that R6/1 mice display reduced STEP protein levels in the striatum and cortex, and increased phosphorylation levels in the striatum, cortex and hippocampus. R6/2, Tet/HD94 and Hdh Q7/Q111 mice striatum also displays decreased STEP protein and increased STEP phosphorylation levels (Saavedra et al., 2011) . The early increase in striatal STEP phosphorylation levels correlates with a dysregulation of the PKA pathway that together with decreased calcineurin activity at later stages further contributes to an enhancement of STEP inactivation. Accordingly, the levels of phosphorylated ERK2 and p38, two targets of STEP, are increased in R6/1 mice striatum at advanced stages of the disease (Saavedra et al., 2011) .
HD mouse models develop resistance to excitotoxicity Hansson et al., 1999 Hansson et al., , 2001 Jarabek et al., 2004; Torres-Peraza et al., 2008) , and reduced levels of calcineurin expression and activity can contribute to this phenomenon (Xifro et al., 2009) . Stimulation of NMDARs activates STEP in a calcineurin-dependent manner (S. , and disruption of STEP activity has been shown to lead to the activation of ERK1/2 signaling and to the attenuation of excitotoxic-induced cell death in the hippocampus (Choi et al., 2007) . Therefore, we wondered whether STEP acts as a calcineurin target after an excitotoxic stimulus to the striatum thereby contributing to the resistance to excitotoxicity observed in HD mouse models. After intrastriatal quinolinic acid injection, we observed higher and unaltered pSTEP levels, and more sustained ERK signaling in R6/1 than in wild-type mice suggesting that STEP inactivation could mediate neuroprotection in R6/1 striatum (Saavedra et al., 2011) . These findings are consistent with lower calcineurin activation which, importantly, correlates with reduced cell death in R6/1 mice striatum after quinolinic acid injection (Xifro et al., 2009) . In agreement with a protective role for STEP inactivation, blockade of STEP activity with FK-506 (an inhibitor of calcineurin) allows ERK activation and confers protection to hilar interneurons of the hippocampus against excitotoxicity (Choi et al., 2007) , and intrastriatal infusion of TAT-STEP, a cell-permeable form, increases quinolic acid-induced cell death in the striatum (Saavedra et al., 2011) . Conversely, low striatal STEP levels and activity (increased pSTEP levels) in R6/1 mice can contribute to their reduced vulnerability to excitotoxicity (Saavedra et al., 2011) .
Activation of extra-synaptic NMDARs in primary cortical neurons leads to calpainmediated cleavage of STEP 61 . This prevents STEP from binding to its substrates and contributes to the selective activation of extra-synaptically concentrated p38 (Xu et al., 2009) . In contrast, synaptic NMDAR stimulation leads to the ubiquitination and degradation of STEP 61 and ERK1/2 activation (Xu et al., 2009 ). We did not observe STEP 61 cleavage or p38 activation which, together with ERK2 activation, suggests a preferential stimulation of synaptic NMDARs in our model (Saavedra et al., 2011) . This is relevant because an imbalance between synaptic and extra-synaptic NMDARs has been shown to occur in YAC128 mice Okamoto et al., 2009 ). However, these mice develop resistance to excitotoxicity with age , and those studies were performed in vulnerable mice. Thus, it is likely that increased extra-synaptic NMDARs during excitotoxicity-sensitive stages might increase STEP 61 cleavage to STEP 33 enabling higher activation of p38 than in wild-type mice. In contrast, in resistant mice other mechanisms should regulate striatal cell survival in response to excitotoxicity and, according with our findings, STEP regulation of ERK activity seems to play an important role (Saavedra et al., 2011) . Fig. 4 . Regulation of STEP levels and activity in the R6/1 mouse striatum during the progression of the disease. The presence of mhtt in the striatum alters this system at different levels: (1) At early stages mhtt induces a down-regulation of STEP mRNA and protein levels, and a dysregulation of the PKA pathway that correlates with increased STEP phosphorylation. (2) At late stages, calcineurin activity is also reduced further inactivating STEP with a consequent increase of pERK2 levels (p-p38 levels and possibly other nonanalyzed STEP targets). Decreased STEP activity, through the regulation of its targets, could be involved in the development of resistance to excitotoxicity in R6/1 mice striatum. (scheme from Saavedra et al., 2011) .
STEP has recently been implicated in the etiology of Alzheimer's Disease Snyder et al., 2005; but the alterations in the STEP pathway found in HD mouse models are specific because STEP protein levels and activity, in contrast to that observed in Alzheimer's Disease, are reduced in HD (Saavedra et al., 2011) . Since the genetic reduction of STEP levels reverses cognitive and cellular deficits in Alzheimer's Disease mice (Y. Zhang et al., 2010) , the modulation of STEP levels might be a good therapeutic strategy in HD. Nevertheless, the possibility of restoring STEP expression in HD is presently hampered by the lack of data about the regulation of STEP gene expression.
MAP kinase phosphatases (MKPs)
MKPs are intracellular dual Tyr phosphatases with an expression restricted to different subcellular compartments (S. . Some of these MKPs, such as MKP-1, -2, -3 and -X, have been shown to be expressed in the brain with a specific distribution and different substrate preferences. MKP-1 is expressed in the cortex, thalamus, striatum and cerebellum with the following substrate specificity: p38>JNK/SAPK>>ERK Franklin & Kraft, 1997; Misra-Press et al., 1995; Takaki et al., 2001) . MKP-2 is localized in the prefrontal cortex, hippocampus and cerebellum and inactivates ERK and JNK/SAPK with the same specificity, but it can also act on p38 (Chu et al., 1996; Dwivedi et al., 2001; Groom et al., 1996; Misra-Press et al., 1995) . MKP-3 is detected in the cerebral cortex, striatum and hippocampus acting preferentially on ERK, but it can also inactivate JNK/SAPK and p38 with the same specificity Muda et al., 1996a,b; Takaki et al., 2001 ). Finally, MKP-X is expressed throughout the brain and acts preferentially on ERK, although it can also dephosphorylate p38 Dowd et al., 1998; Muda et al., 1996b; Shin et al., 1997) .
Although they are expressed in the brain, their role in neuronal function is not well established. MKP-1 increases in rat brain after limbic epilepsy (Gass et al., 1996) and, together with MKP-3, upon cerebral hypoxia in neuronal nuclei of newborn piglets (Mishra & Delivoria-Papadopoulos, 2004) . Moreover, both MKP-1 and -3 play important roles in neural plastic modifications after drug exposure (Takaki et al., 2001) , whereas MKP-2 is increased in postmortem brains of suicide subjects with major depression (Dwivedi et al., 2001) . Recently, it has been shown that MKP-1 controls axon branching of cortical neurons in response to the trophic factor BDNF (Jeanneteau et al., 2010) . In addition, in PC12 cells, oxidative stress and hypoxia increase MPK-1 expression, while trophic factor treatment upregulates both MKP-1 and -3 Keyse & Emslie, 1992; Seta et al., 2001 ). Thus, regulation of MPKs seems to be important not only after brain injury, but also during development.
In a stable PC12 cell line expressing truncated mhtt with 118Q, Z. L. Wu and colleagues (2002) showed that MKP-1 and -3 mRNA levels, and MKP-1 protein levels, were increased at different time points after mhtt expression. In good correlation with changes in MKPs levels, they observed a substantial reduction of ERK1/2 phosphorylation. Interestingly, treatment with sodium orthovanadate and bp V (pic), two general Tyr phosphatase inhibitors, rescues cells from polyQ-induced cell death suggesting that these phosphatases are involved in mhtt-induced toxicity (Z. L. Wu et al., 2002) . In HEK 293 cells transfected with NR1/NR2B and htt containing 138Q, MKP-2 has been shown to be reduced in the soluble fraction and increased in the particulate-derived fraction when compared with cells expressing htt with 15Q (Fan et al., 2008) . However, the mechanism underlying this redistribution and the physiological significance of this event are presently unknown.
Conclusion
Understanding the pathways by which mhtt causes neuronal dysfunction and death is essential to develop efficient treatments for HD. Great progress has been made over the last years in highlighting the molecular mechanisms affected by mhtt. Here, we have reviewed the existing data about changes in the expression and regulation of phosphatases in HD models and human HD brain. From these results, it is becoming increasingly clear that alterations in phosphatases are involved in the pathogenesis of HD. So far, the phosphatases analyzed participate in the regulation of excitotoxicity and neuronal survival (through the regulation of the PI3K/Akt pathway, ERK2 and/or htt phosphorylation). In mouse models, most of them are decreased, which seems to be a compensatory mechanism induced in response to mhtt expression in order to prevent neuronal cell death. However, how this might translate to humans is still unknown as we cannot follow the disease from the beginning, and analysis of phosphatase levels and activity can be performed only at late stages of the disease. We believe that the regulation of phosphatases is a new and promising approach to treat HD. Therefore, our future challenge is to develop novel tools to treat HD based on these findings. In addition, phosphatases are also involved in the pathogenesis of other neurodegenerative disorders, and ongoing investigations of disease mechanisms in HD can also provide new therapeutic approaches to Parkinson's or Alzheimer's Diseases.
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